Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysis

Department of Pediatrics, Zagazig University, Zagazig, Egypt.
Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 07/2012; 23(4):755-64. DOI: 10.4103/1319-2442.98157
Source: PubMed


Children with chronic kidney disease are at high risk for growth retardation and decreased adult height. Growth hormone (GH) treatment is known to stimulate growth in children with short stature suffering from chronic kidney disease. However, the extent to which this therapy affects final adult height is not known. This study was performed on 15 patients with end-stage renal disease (ESRD) on regular hemodialysis to detect the effect of using recombinant human growth hormone (rhGH) on growth of patients with ESRD on regular hemodialysis and comparing this effect with the growth velocity in the same group without using rhGH in the year before therapy. There were eight females and seven males with mean age 10.6 ± 2.8 (range 5-14 years). For each patient, recombinant GH was given for one year, three-times weekly. The data of these 15 patients was compared with the year before treatment versus data of the same group of patients after six months and after one year of rhGH therapy. Our results showed that, in the year before therapy, height of these patients increased from a mean of 112.1 ± 11.6 cm to 112.7 ± 11.5 cm, which is a non-significant increase statistically (P >0.05) as well as clinically (mean growth velocity 0.6 cm/year), while height of these patients increased from a mean of 112.7 ± 11.5 cm at the start of therapy to 116.8 ± 11 cm after therapy for one year, which, although statically not significant (P >0.05), was of clinical significance as it makes rate of increase, i.e. the mean growth velocity, 4.1 cm/year close to the normal growth velocity, which is 5 cm/year, before puberty. rhGH therapy for patients with ESRD on regular hemodialysis is helpful in height gain and catch-up growth even when given three-times per week instead of five- or six-times per week. We recommend giving rhGH therapy as a routine supplementation to pediatric patients before epiphyseal closure.

Download full-text


Available from: Doaa Youssef
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The aim of this study is to evaluate growth in Egyptian children with chronic Kidney disease (CKD) on haemodialysis and investigate its relation to the degree of anemia and metabolic acidosis. Methods: The study included 70 Egyptian children from 7.3 to13.1 years old on regular haemodialysis at the haemodialysis unit of AL-Zahraa hospital, AL-Azhar University and the Hemodialysis Unit of the Centre of Pediatric Nephrology and Transplantation of Cairo University. Body weight, height, mid upper arm circumference, and skinfolds thickness were measured. All measurements were expressed as standard deviation score (SDS). Tanner-Whitehouse (TW) method was used for the assessment of bone age. Complete blood picture count, arterial blood gases (predialysis), serum calcium, phosphorus and alkaline phosphatase were measured. Results: The present study shows that 77.1% of patients had short stature and 28.57 % had delayed bone age. The ratio of bone age to height age was 1.46. Growth retardation was significantly related with the degree of anemia and degree of metabolic acidosis. Conclusions: The study emphasizes that bone age is less affected than height age. Thus, the possibility of catch-up growth can be suggested. The study recommends correction of anemia and metabolic acidosis to improve growth and should be targeted prior to consideration of growth hormone therapy.
    No preview · Article · Dec 2012
  • [Show abstract] [Hide abstract]
    ABSTRACT: Besides their growth-promoting properties, GH and IGF-1 regulate a broad spectrum of biological functions in several organs, including the kidney. This review focuses on the renal actions of GH and IGF-1, taking into account major advances in renal physiology and hormone biology made over the last 20 years, allowing us to move our understanding of GH/IGF-1 regulation of renal functions from a cellular to a molecular level. The main purpose of this review was to analyze how GH and IGF-1 regulate renal development, glomerular functions, and tubular handling of sodium, calcium, phosphate, and glucose. Whenever possible, the relative contributions, the nephronic topology, and the underlying molecular mechanisms of GH and IGF-1 actions were addressed. Beyond the physiological aspects of GH/IGF-1 action on the kidney, the review describes the impact of GH excess and deficiency on renal architecture and functions. It reports in particular new insights into the pathophysiological mechanism of body fluid retention and of changes in phospho-calcium metabolism in acromegaly as well as of the reciprocal changes in sodium, calcium, and phosphate homeostasis observed in GH deficiency. The second aim of this review was to analyze how the GH/IGF-1 axis contributes to major renal diseases such as diabetic nephropathy, renal failure, renal carcinoma, and polycystic renal disease. It summarizes the consequences of chronic renal failure and glucocorticoid therapy after renal transplantation on GH secretion and action and questions the interest of GH therapy in these conditions.
    No preview · Article · Jan 2013 · Endocrine reviews
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Growth is impaired in a chronic renal failure. Anemia, acidosis, reduced intake of calories and protein, decreased synthesis of vitamin D and increased parathyroid hormone levels, hyperphosphatemia, renal osteodystrophy and changes in growth hormone-insulin-like growth factor and the gonadotropin-gonadal axis are implicated in this study. Growth is adversely affected by immunosuppressives and corticosteroids after kidney transplantation. Treating metabolic disorders using the recombinant human growth hormone is an effective option for patients with inadequate growth rates.
    Preview · Article · Feb 2015 · Eurasian Journal of Medicine